Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Deutenzalutamide on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Deutenzalutamide is an oral hormone-blocking medicine for advanced prostate cancer. It was developed in China by Hinova Pharmaceuticals, where it is sold as 海纳安®, and it is taken as soft capsules once a day.
China's National Medical Products Administration (NMPA) approved it in May 2025 for adult men with metastatic castration-resistant prostate cancer (mCRPC) who:
It is a prescription cancer medicine and should only be used under a urologist or medical oncologist.
Prostate cancer cells grow when male hormones (androgens) attach to the androgen receptor inside the cell. Deutenzalutamide is a second-generation androgen receptor inhibitor: it blocks this receptor so the growth signal is switched off, even when the cancer no longer responds to castration alone. Some of its hydrogen atoms are replaced with deuterium, a heavier form of hydrogen. This slows the way the body breaks it down and, according to the developer, means less of it reaches the brain, which is linked to fewer side effects such as seizures and falls.
The phase 3 HC-1119-04 trial, published in Signal Transduction and Targeted Therapy in 2026, included 417 men at 36 centres in China. All had already received the testosterone-blocking tablet, and about two-thirds had also had chemotherapy. Compared with placebo, deutenzalutamide lowered the risk of the cancer growing on scans, or death, by 42%. The median time to progression was 5.55 months against 3.71 months, but the benefit lasted in a meaningful group: 29% were still progression-free at 12 months, compared with 6%, and 18% at 24 months.
The main overall survival analysis did not show a clear difference (hazard ratio 0.95), largely because many men in both groups went on to other treatments. Analyses adjusting for those later treatments suggested a survival benefit (hazard ratios 0.65 to 0.73).
If a dose is forgotten, take it as soon as you remember that day. If a whole day is missed, simply take the normal dose the next day; do not double up.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Anaemia: this was the most common side effect in the HC-1119-04 trial, affecting 44.2% of men on deutenzalutamide and 39.3% on placebo, and was severe in 16.4% against 10.7%. Blood counts are checked during treatment, so report tiredness, breathlessness or paleness.
Overall: severe side effects of any cause occurred in 52.9% of men on deutenzalutamide and 42.1% on placebo; severe side effects judged to be treatment-related occurred in 22.3% against 15.0%. 8.4% stopped because of side effects, compared with 7.9% on placebo. Deaths linked to adverse events were reported in 2.2% and 3.6% respectively. This medicine is for men only and has not been studied in children.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For men whose prostate cancer carries HRR gene changes, our page on Talzenna covers another import option.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. At two 40 mg capsules a day, a month of treatment needs about 60 capsules, and we plan supply so there is no break between orders. The capsules travel in their sealed original packs under temperature-controlled shipping and should then be stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid specialist's prescription.
Urology and oncology centres in Delhi treat advanced prostate cancer patients from across North India, and dispatch from New Delhi keeps delivery quick.
Capsules can be delivered to the patient's home or the hospital pharmacy before the current supply runs out.
Uro-oncologists in Bangalore can request the medicine for a named patient, with the quote shared before ordering.
Patients at Chennai's cancer hospitals can receive their monthly supply at the treating centre.
We plan each shipment so the once-daily capsules continue without interruption.
Men in Kolkata and the eastern states can use the same documented import route.
Families in Pune receive updates at every step, from prescription check to delivery.
The treating doctor can send the prescription, PSA history and scan reports to start the import.
Supply for patients treated in Vellore can be sent directly to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate delivery to urology and cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive their capsules in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
